Stay updated with breaking news from Improve Quality. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
“The global laboratory information management systems market is projected to grow at a CAGR of 12.1% during the forecast period (2020–2025)” The globa
North America and Asia Pacific to Thrive on Back of Large Patient Base, Numerous Therapies Emerge to Improve Quality of Life for Target Patients Growing Number of People Visiting Aesthetic
News Release | 29 April 2021 MANILA, PHILIPPINES (29 April 2021) — Improving quality of life, and social and economic opportunities in Asia’s fast-growing cities are instrumental in fulfilling their potential as engines of economic prosperity and hubs for sustainability, says Creating Livable Asian Cities, a new book released today by the Asian Development Bank (ADB). The publication examines the region’s urbanization challenges and presents solutions across five priority areas: smart and inclusive urban planning; sustainable transport that provides equitable access to services and opp...
Sanofi: New Dupixent (dupilumab) analyses reinforce long-term safety and efficacy profile in patients with atopic dermatitis as young as 6 years as young as 6 years Nearly 30 data presentations at AAD and ESPD across clinical and real-world settings, including the impact of Dupixent on disease measures in uncontrolled moderate-to-severe atopic dermatitis Late-breaking Phase 2 data for rilzabrutinib, an investigational therapy for pemphigus vulgaris, a rare, debilitating autoimmune disease, to be presented at AAD PARIS - April 23, 2021 - New analyses from Dupixent (dupilumab) trials evaluat...
Share this article TARRYTOWN, N.Y., April 23, 2021 /PRNewswire/ -- Nearly 30 data presentations at AAD and ESPD highlight the impact of Dupixent on disease measures including rapid itch relief and sustained improvement in disease severity, as well as quality of life in clinical and real-world settings Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that new analyses of Dupixent ® (dupilumab) in patients as young as 6 years with moderate-to-severe atopic dermatitis will be presented at the American Academy of Dermatology Annual Meeting (AAD VMX 2021) from April 23-25, and at ...